M72 TB Vaccine: A New Hope for TB Prevention

Wits RHI is contributing to the landmark Phase 3 M72/AS01E TB vaccine trial, advancing research towards a new generation of TB prevention.

Tuberculosis remains one of the world’s biggest infectious disease challenges. Wits RHI, led by Professor Lee Fairlie, is contributing to the Phase 3 M72/AS01E vaccine trial, an important global effort to develop a new TB vaccine. The research places African clinical research capacity at the centre of efforts to transform TB prevention.